Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
34.15 EUR | +1.19% | +0.89% | -15.09% |
02/02 | Boiron: nearly 600,000 shares tendered to the OPAS | CF |
11/01 | Boiron: OPAS open from January 11 to 31 | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.59 for the current period. Therefore, the company is undervalued.
- The company has a low valuation given the cash flows generated by its activity.
- Analyst opinion has improved significantly over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.09% | 626M | B | ||
+35.04% | 5.92B | B- | ||
-15.13% | 4.51B | C+ | ||
-9.75% | 3.15B | B- | ||
+2.14% | 3.1B | C | ||
-6.82% | 2.42B | - | D+ | |
+47.87% | 1.97B | - | ||
-7.89% | 1.68B | - | - | |
+0.09% | 1.65B | - | - | |
-12.97% | 1.53B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BOI Stock
- Ratings BOIRON